Clinical advances in antibody-drug conjugates for hematological malignancies
An antibody-drug conjugate (ADC) is a targeted therapeutic drug composed of a monoclonal antibody linked to a small-molecule cytotoxic drug via a linker. Once administered, ADCs bind to tumor-specific antigens, forming ADC-antigen complexes, which are internalized through endocytosis. The linkers ar...
Saved in:
| Main Authors: | TANG Sijie, MI Jianqing |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Office of Journal of Shanghai Jiao Tong University (Medical Science)
2024-12-01
|
| Series: | Shanghai Jiaotong Daxue xuebao. Yixue ban |
| Subjects: | |
| Online Access: | https://xuebao.shsmu.edu.cn/article/2024/1674-8115/1674-8115-2024-44-12-1607.shtml |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies
by: Yuying Jiang, et al.
Published: (2025-02-01) -
Antibody-drug conjugates in cancer therapy: applications and future advances
by: Rou Long, et al.
Published: (2025-05-01) -
Editorial: Antibody-drug conjugates in solid and hematologic malignancies
by: Khalil Saleh, et al.
Published: (2025-08-01) -
Antibody drug conjugates in the clinic
by: Edidiong Udofa, et al.
Published: (2024-11-01) -
Exploration of the antibody–drug conjugate clinical landscape
by: Heather Maecker, et al.
Published: (2023-12-01)